Back to Results
First PageMeta Content
Medical emergencies / Aging-associated diseases / Bristol-Myers Squibb / Clopidogrel / Organochlorides / Prodrugs / Percutaneous coronary intervention / Antiplatelet drug / Myocardial infarction / Medicine / Cardiology / Chemistry


FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting Date: 15 April 2015
Add to Reading List

Open Document

File Size: 3,99 MB

Share Result on Facebook

City

PHOENIX / /

Company

ADP / The Medicines Company / /

Country

United States / /

Currency

IDR / /

Event

FDA Phase / /

Facility

FDA White Oak Campus / White Oak Conference Center / 3a complex / /

MedicalCondition

intra-procedural stent thrombosis / acute coronary syndromes / stable angina undergoing PCI / myocardial necrosis / stent thrombosis / acute coronary syndrome / coronary artery disease undergoing / myocardial infarction / coronary artery disease / stable angina / angina / stent thromboses / /

MedicalTreatment

surgery / oral therapy / /

Organization

office of Drug Evaluation / FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research / Food and Drug Administration / Review Division / Renal Drugs Advisory Committee / FDA / Renal Advisory Committee / Society for Cardiovascular Angiography and Interventions / Cardiovascular and Renal Advisory Committee / Cardiac and Renal Drug Advisory Committee / Advisory Committee / Cardiovascular and Renal Drugs Advisory Committee / /

Position

investigator / Deputy Director Memo Second Cycle Clinical Summary Second Cycle Statistical Summary Second Cycle Clinical Pharmacology Summary Office / /

Product

clopidogrel / adenosine / P2Y12 / Sponsor / /

ProvinceOrState

Michigan / /

Technology

PHOENIX protocol / CAD / /

URL

http /

SocialTag